GSK2890457 + metformin

GSK2890457 + metformin is a combination investigational therapy comprising GSK2890457, a novel agent whose mechanism of action and class have not been disclosed in detail in public sources, and metformin, a well-known biguanide oral antidiabetic drug. GSK2890457 has been studied in first-in-human clinical trials for safety and tolerability in participants with type 2 diabetes, with at least one study specifying oral administration as a 5 g kit[2][4][6][8]. Metformin acts primarily by decreasing hepatic glucose production and improving insulin sensitivity, and is widely used as first-line therapy in type 2 diabetes[1][3]. The combination is intended for glycemic control in adults with type 2 diabetes mellitus.